NEW YORK (GenomeWeb) – MyoKardia said today that it is collaborating with 23andMe to create a patient community to advance research into hypertrophic cardiomyopathy (HCM), a progressive and frequently debilitating disease characterized by excessive contractility of the heart.
Under the terms of the partnership, the companies will create a patient community where 23andMe customers can access regularly updated disease information and HCM research opportunities. The companies noted that more than 6,000 HCM patients are currently 23andMe customers.